ARTICLE | Deals
Something old, something new: what’s next for Zai’s dealmaking
As deal with Seagen brings local rights to first-in-class ADC, COO Smiley is looking ahead to a broader set of opportunities
September 30, 2022 4:43 PM UTC
While Zai’s deal with Seagen for antibody-drug conjugate Tivdak is squarely in its in-licensing wheelhouse, the biotech is looking to expand its dealmaking remit to include much broader China deals, as well as partnerships involving U.S. rights.
In a deal announced Tuesday, Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) gained rights to Tivdak tisotumab vedotin-tftv from Seagen Inc. (NASDAQ:SGEN) in mainland China, Hong Kong, Macau and Taiwan...